John F. Harms

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 284 citations

Medicine, Neuroscience, Pharmacology +13

Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis

Judith A. Siuciak, Douglas S. Chapin, John F. Harms et al. · Neuropharmacology · 2006 · 274 citations

Medicine, Neuroscience, Pharmacology +12

Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 <i>H</i> -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).

Patrick R. Verhoest, Douglas S. Chapin, Michael L. Corman et al. · Journal of Medicinal Chemistry · 2009 · 201 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Kinetics of Metastatic Breast Cancer Cell Trafficking in Bone

Pushkar Phadke, Robyn R. Mercer, John F. Harms et al. · Clinical Cancer Research · 2006 · 121 citations · Full text

Medicine, Cell Biology, Oncology +17

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models

Vahri Beaumont, Sheng Zhong, Hai Lin et al. · Neuron · 2016 · 121 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17